Meeting
2012 ASCO Annual Meeting
TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC).
Authors
Edwina S. Baskin-Bey
Astellas Pharma Europe, Ltd., Staines, United Kingdom
Edwina S. Baskin-Bey , Neal D. Shore , Kenya Barber , Taoufik Ouatas , Axel Heidenreich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01288911
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS4698^)
Abstract #
TPS4698^
Poster Bd #
17A
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2018 Genitourinary Cancers Symposium
c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression.
First Author: William Kevin Kelly
Poster
2012 Genitourinary Cancers Symposium
Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.
First Author: Howard I. Scher
Poster
2022 ASCO Genitourinary Cancers Symposium
PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.
First Author: Giulio Francolini